These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15000599)

  • 1. Supreme Court decision on genotypic tests for antiretroviral drugs resistance: Joint Criminal Divisions.
    Dianzani F; Frascione E
    Scand J Infect Dis Suppl; 2003; 106():108-9. PubMed ID: 15000599
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral resistance.
    Geretti AM
    J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
    [No Abstract]   [Full Text] [Related]  

  • 3. Study of different systems for interpreting results of genotypic antiretroviral drug resistance tests.
    García F; Palomares JC; Martínez NM; Alvarez M; Suarez S; García F; Rodríguez JM; Quero JH; del Carmen Maroto M
    Antivir Ther; 2003 Jun; 8(3):251-2. PubMed ID: 12924543
    [No Abstract]   [Full Text] [Related]  

  • 4. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
    Aceti A; Carosi G
    Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?
    Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF;
    Antivir Ther; 2006; 11(3):305-14. PubMed ID: 16759046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic resistance tests for the management of postexposure prophylaxis.
    Puro V
    Scand J Infect Dis Suppl; 2003; 106():93-8. PubMed ID: 15000596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An updated guide to genotype interpretation.
    MacArthur RD
    AIDS Read; 2004 May; 14(5):256-8, 261-4, 266. PubMed ID: 15199855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral drug resistance and resistance testing.
    Gallant JE
    Top HIV Med; 2005 Dec-2006 Jan; 13(5):138-42. PubMed ID: 16377851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients.
    Parisi SG; Boldrin C; Cruciani M; Nicolini G; Cerbaro I; Manfrin V; Dal Bello F; Franchin E; Franzetti M; Rossi MC; Cattelan AM; Romano L; Zazzi M; Andreoni M; Palù G
    J Clin Microbiol; 2007 Jun; 45(6):1783-8. PubMed ID: 17442799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and significance of minority quasispecies of drug-resistant HIV-1.
    Metzner KJ
    J HIV Ther; 2006 Dec; 11(4):74-81. PubMed ID: 17578210
    [No Abstract]   [Full Text] [Related]  

  • 11. Study on mutations and antiretroviral therapy (SMART): preliminary results.
    Gianotti N; Moretti F; Tambussi G; Racca S; Presi S; Crucianelli R; Carrera P; Ferrari M; Lazzarin A
    Antivir Ther; 1999; 4 Suppl 3():65-9. PubMed ID: 16021873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Algorithms for the interpretation of HIV-1 genotypic drug resistance information.
    Vercauteren J; Vandamme AM
    Antiviral Res; 2006 Sep; 71(2-3):335-42. PubMed ID: 16782210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefits and limitations of testing for resistance to HIV drugs.
    Richman DD
    J Antimicrob Chemother; 2004 Apr; 53(4):555-7. PubMed ID: 15014064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 genotypic drug-resistance interpretation algorithms need to include hypersusceptibility-associated mutations.
    Wang K; Samudrala R; Mittler JE
    J Infect Dis; 2004 Dec; 190(11):2055-6; author reply 2056. PubMed ID: 15529272
    [No Abstract]   [Full Text] [Related]  

  • 15. Minority HIV mutation detection in dried blood spots indicates high specimen integrity and reveals hidden archived drug resistance.
    Wei X; Youngpairoj AS; Garrido C; Zahonero N; Corral A; de Mendoza C; Heneine W; Johnson JA; Garcia-Lerma JG
    J Clin Virol; 2011 Feb; 50(2):148-52. PubMed ID: 21130027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brief summary of the legal proceeding.
    Nicastri E
    Scand J Infect Dis Suppl; 2003; 106():105-7. PubMed ID: 15000598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    Zolopa AR
    J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 antiretroviral resistance testing laboratories.
    Hofherr LK; Francis DP; Astles JR; Schalla WO
    Clin Lab Sci; 2002; 15(4):213-9. PubMed ID: 12776781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.